The main objective of this core Is the enrollment of every patient AML and MDS referred to Washington University into the Tissue Acquisition and Clinical Database protocol of the GAML program project. Skin, oral mucosa, bone marrow, peripheral blood leukocytes and serum specimens collected from patients will be banked and processed by Core B, the Specimen Acquisition, Genomic, Transcriptomic, and Epigenetic Profiling Core, whereupon they will serve as the basis for genomic analyses outlined In Core C, to be utilized in Projects 1-4. This Clinical Core will also maintain and expand a comprehensive database that captures essential clinical, pathological, karyotypic, molecular, therapeutic, and outcomes data of enrolled AML and MDS patients, anonymously linked with the corresponding tissue specimens. The Clinical Core database will provide key clinical annotation that, in conjunction with gene expression data generated by Core B and DNA sequence data generated by Core C, which will be utilized by Projects 1-4. A.1.
Specific Aim 1 : We will prospectively collect and bank tissue for analysis at diagnosis, in remission, and at relapse from every patient referred to the Washington University Siteman Cancer Center with AML and MDS. A.2.
Specific Aim2 : We will maintain a comprehensive clinical leukemia database that will capture epidemiological data, disease-related characteristics, prognostic factors, therapeutic information, and outcomes data from all enrolled AML and MDS patients, with de-identified linkage to corresponding banked tissue specimens.
The specimens collected and the database maintained by Core A are essential to the success of Projects 1- 4 outlined in this proposal. These have served as a unique and invaluable resource both for this Program Project since Its inception, and for extramural projects (TCGA) as well.
|Fisher, D A C; Malkova, O; Engle, E K et al. (2017) Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31:1962-1974|
|Uy, G L; Duncavage, E J; Chang, G S et al. (2017) Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia 31:872-881|
|Cole, Christopher B; Russler-Germain, David A; Ketkar, Shamika et al. (2017) Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest 127:3657-3674|
|Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13|
|Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558|
|Duncavage, Eric J; Uy, Geoffrey L; Petti, Allegra A et al. (2017) Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood 129:1397-1401|
|Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060|
|Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2017) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant :|
|Zhang, Jin; Griffith, Malachi; Miller, Christopher A et al. (2017) Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes. Exp Hematol 55:19-33|
|Ali, Alaa M; Weisel, Daniel; Gao, Feng et al. (2017) Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med 6:2814-2821|
Showing the most recent 10 out of 113 publications